Metabolic Comparison of Radiolabeled Bleomycin and Bleomycin-Glucuronide Labeled with 99m Tc
- 1 October 2011
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 26 (5) , 573-584
Abstract
The metabolic comparison of bleomycin (BLM) and bleomycin-glucuronide (BLMG) radiolabeled with 99mTc (99mTc-BLM and 99mTc-BLMG, respectively) has been investigated in this study. Quality control procedures were carried out using thin-layer radiochromatography and high-performance liquid chromatography. To compare the metabolic behavior of BLM and its glucuronide conjugate radiolabeled with 99mTc, scintigraphic, and biodistributional techniques were applied using male New Zealand rabbits and Albino Wistar rats. The results obtained have shown that these compounds were successfully radiolabeled with a labeling yield of about 100%. Maximum uptakes of 99mTc-BLM and 99mTc-BLMG metabolized as N-glucuronide were observed within 2 hours in the liver, the bladder, and the spinal cord for 99mTc-BLM and the lung, the liver, the kidney, the large intestine, and the spinal cord for 99mTc-BLMG, respectively. Scintigraphy and biodistributional studies performed on the experimental animals have shown that radiopharmaceutical potentials of these compounds are completely different. At the same time, uptake of the 99mTc-BLMG was found to be better than that of 99mTc-BLM.Keywords
This publication has 26 references indexed in Scilit:
- In vivo biodistribution of 131I labeled bleomycin (BLM) and isomers (A2 and B2) on experimental animal modelsJournal of Radioanalytical and Nuclear Chemistry, 2010
- Membrane-localized activation of glucuronide prodrugs by β-glucuronidase enzymesCancer Gene Therapy, 2006
- Bleomycins: towards better therapeuticsNature Reviews Cancer, 2005
- Protective mechanisms against the antitumor agent bleomycin: lessons from Saccharomyces cerevisiaeCurrent Genetics, 2003
- Cancer chemotherapy: A SN-38 (7-Ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug monoTherapy) strategyBioorganic & Medicinal Chemistry Letters, 2003
- Beta-Glucuronidase-Mediated Drug ReleaseCurrent Pharmaceutical Design, 2002
- Expression and function of β-glucuronidase in pancreatic cancer: potential role in drug targetingNaunyn-Schmiedeberg's Archives of Pharmacology, 2000
- Potential Use of Radiolabeled Glucuronide Prodrugs with Auger and/or Alpha Emitters in Combined Chemo- and Radio-Therapy of CancerCurrent Pharmaceutical Design, 2000
- Effect of Food and Gastric pH on the Bioavailability of GrepafloxacinClinical Pharmacokinetics, 1997
- The influence of experimental conditions on the efficiency of labeling of bleomycin with 99Tcm, using Sn(II) as the reductantThe International Journal of Applied Radiation and Isotopes, 1978